Unicycive Therapeutics Inc 2026年度季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).☐Yes☒No Securities registered pursuant to Section 12(b) of the Act: As of May 12, 2026, there were 26,700,027 shares of the Company’s common stock, par value $0.001 per share, issued andoutstanding. TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Statements of Operations and Comprehensive Income (Loss) (Unaudited) – Three months ended March, 2025and 20262 Statements of Stockholders’ Equity (Unaudited) – Three months ended March 31, 2025 and 20263 PART I – FINANCIAL INFORMATION Unicycive Therapeutics, Inc.Balance Sheets Unicycive Therapeutics, Inc.Statements of Stockholders’ Equity(In thousands, except share amounts) Unicycive Therapeutics, Inc.Statements of Cash Flows(In thousands) Unicycive Therapeutics, Inc.Notes to the Financial Statements 1. Organization and Description of Business Overview Unicycive Therapeutics, Inc. (“we”, “the Company”) was incorporated in the State of Delaware on August 18, 2016. The Company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte. Ltd, a Singapore-based corporation, (“Sphaera”)(Note 4). UNI 494 is a pro-drug of Nicorandill that is being developed as a treatment for acute kidney injury. In September 2018, the Company purchased a second drug candidate, Renazorb RZB 012 and its trademark, RENALAN, and variouspatents from Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Note 4). Renazorb (“oxylanthanum carbonate”) is being developed for the The Company continues to evaluate the licensing of additional technologies and drugs in order to pursue development, regulatory Liquidity The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but notlimited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on keypersonnel, compliance with governmental regulations and the need to obtain additional financing to fund operations. The Company’s The Company has incurred operating losses and negative cash flows from operations since inception and expects to continue to incurnegative cash flows from operations in the future. As the Company continues its drug development activities, the operating losses areexpected to increase. The Company has historically relied on private equity offerings, debt financing and loans from a stockholder to In connection with its initial public offering (“IPO”), on July 13, 2021, the Company began trading on the Nasdaq Capital Marketunder the symbol “UNCY”, and on July 15, 2021, received approximately $22.3 million in net proceeds after deducting theunderwriting discounts, commissions and other offering expenses. The Company has used the net proceeds from the IPO to complete On March 3, 2023, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investorsthat may provide up to $130.0 million in gross proceeds through a private placement and that included initial upfront funding of $30.0 On March 13, 2024, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investorsto provide $50.0 million in gross proceeds through a private placement. Pursuant to the securities purchase agreement, the Company On November 13, 2024, the Company entered into a sales agreement, with Guggenheim Securities, LLC as amended by AmendmentNo. 1 thereto dated November 14, 2025 (as amended, the “Sales Agreement”) pursuant to which, we may offer and sell shares ofcommon stock having an aggregate offering price of up to $100.0 million, subject to certain limitations and in accordance with the During the quarter ended March 31, 2026, the Company sold 3,123,537 shares of common stock pursuant to a sales agreement, withGuggenheim Securities, LLC, at an average price of $6.46 per share and paid $0.6 million in commissions, resulting in net proceeds to The Company expects to continue incurring losses in the future and will be required to raise additional capital in the future to completeits planned clinical trials, pursue product development initiatives and penetrate markets for the sale of its products. Managementbelieves that the Company will continue to have access to capital resources through possible equity offerings, debt financings,corporate collaborations or other means. There can be no assurance that the Company will be able